{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:21:48Z","timestamp":1792059708418,"version":"4.4.0"},"reference-count":83,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2004,5,10]],"date-time":"2004-05-10T00:00:00Z","timestamp":1084147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2004,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Tumor endothelium represents a valuable target for cancer therapy. The vasculature plays a critical role in the survival and continued growth of solid tumor masses; in addition, the inherent differences between tumor blood vessels and blood vessels associated with normal tissue make the tumor vasculature a unique target on which to base the design of novel therapeutics, which may allow highly selective treatment of malignant disease. Therapeutic strategies that target and disrupt the already formed vessel networks of growing tumors are actively being pursued. The goal of these approaches is to induce a rapid and catastrophic shutdown of the vascular function of the tumor so that blood flow is arrested and tumor cell death due to the resulting oxygen and nutrient deprivation and buildup of waste products occurs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Biologic approaches and small\u2010molecule drugs that can be used to damage tumor vasculature have been identified. Physiologic, histologic\/morphologic, and immunohistochemical assessments have demonstrated that profound disruption of the tumor vessel network can be observed minutes to hours after treatment. The small\u2010molecule agents that have made the greatest advances in the clinical setting (5,6\u2010dimethylxanthenone\u20104\u2010acetic acid [DMXAA], combretastatin A4 disodium phosphate [CA4DP], and ZD6126) are the focus of the current review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Loss of patent blood vessels, decreased tumor blood flow, extensive necrosis, and secondary ischemia\u2010induced tumor cell death have been well documented in a variety of preclinical tumor models treated with agents such as DMXAA, CA4DP, and ZD6126. The use of such agents in conjunction with irradiation and other chemotherapeutic agents has led to improved treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>The targeting of tumors' supportive blood vessel networks could lead to improvements in cancer cure rates. It is likely that this approach will prove to be most efficacious when used in concert with conventional treatment strategies. Cancer 2004. \u00a9 2004 American Cancer Society.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.20299","type":"journal-article","created":{"date-parts":[[2004,5,10]],"date-time":"2004-05-10T14:02:41Z","timestamp":1084197761000},"page":"2491-2499","source":"Crossref","is-referenced-by-count":269,"title":["Vascular\u2010targeting therapies for treatment of malignant disease"],"prefix":"10.1002","volume":"100","author":[{"given":"Dietmar W.","family":"Siemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Chaplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Horsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,6,2]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"6449","article-title":"Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review","volume":"49","author":"Vaupel P","year":"1989","journal-title":"Cancer Res."},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-66-783-181"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-2862(77)90141-8"},{"key":"e_1_2_7_5_2","first-page":"467","article-title":"How is blood vessel growth regulated in normal and neoplastic tissue?","volume":"46","author":"Folkman J","year":"1986","journal-title":"Cancer Res."},{"key":"e_1_2_7_6_2","first-page":"4770","article-title":"Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy","volume":"59","author":"Hahnfeldt P","year":"1999","journal-title":"Cancer Res."},{"key":"e_1_2_7_7_2","first-page":"158","volume-title":"Basic clinical radiobiology for radiation oncologists","author":"Horsman MR","year":"2002"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512283332608"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(00)00243-7"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00046365"},{"key":"e_1_2_7_11_2","first-page":"57","article-title":"Tumour vasculature as a target for cancer therapy","volume":"80","author":"Chaplin DJ","year":"1999","journal-title":"Br J Cancer."},{"key":"e_1_2_7_12_2","first-page":"4","article-title":"Vascular targeting agents","volume":"3","author":"Siemann DW","year":"2002","journal-title":"Horizons Cancer Ther."},{"key":"e_1_2_7_13_2","first-page":"283","article-title":"A critique of tumour resistance","volume":"7","author":"Woglom WH","year":"1923","journal-title":"J Cancer Res."},{"key":"e_1_2_7_14_2","first-page":"29","article-title":"A review of the influence of bacterial infection and bacterial products (Coley's toxins) on malignant tumours in man","volume":"274","author":"Coley Nauts H","year":"1953","journal-title":"Acta Med Scand."},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.3499.132"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(83)90426-1"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-8140(94)90010-8"},{"key":"e_1_2_7_18_2","first-page":"6","article-title":"Endothelial cell attack as a novel approach to cancer therapy","volume":"6","author":"Denekamp J","year":"1986","journal-title":"Cancer Top."},{"key":"e_1_2_7_19_2","first-page":"251","article-title":"Proliferation kinetics of endothelial and tumour cells in three mouse mammary carcinomas","volume":"15","author":"Hirst DG","year":"1982","journal-title":"Cell Tissue Kinet."},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1984.66"},{"key":"e_1_2_7_21_2","first-page":"399","article-title":"Anticancer strategies involving the vasculature: vascular targeting and the inhibition of angiogenesis","volume":"3","author":"Bicknell R","year":"1992","journal-title":"Semin Cancer Biol."},{"key":"e_1_2_7_22_2","first-page":"1388","article-title":"Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies","volume":"60","author":"Eberhard A","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_7_23_2","first-page":"1623","article-title":"Up\u2010regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy","volume":"1","author":"Burrows FJ","year":"1995","journal-title":"Clin Cancer Res."},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10378"},{"key":"e_1_2_7_25_2","first-page":"4221","article-title":"Vascular endothelial growth factor and vascular targeting of solid tumors","volume":"21","author":"Brekken RA","year":"2003","journal-title":"Anticancer Res."},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.122157899"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7512751"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5349.377"},{"key":"e_1_2_7_29_2","first-page":"711","article-title":"Targeted delivery of tissue factor to the ED\u2010B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice","volume":"61","author":"Nilsson F","year":"2001","journal-title":"Cancer Res."},{"key":"e_1_2_7_30_2","first-page":"2674","article-title":"Prostate\u2010specific membrane antigen is produced in tumor\u2010associated neovasculature","volume":"5","author":"Chang SS","year":"1999","journal-title":"Clin Cancer Res."},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910630121"},{"key":"e_1_2_7_32_2","first-page":"189","article-title":"Anti\u2010vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate","volume":"19","author":"Chaplin DJ","year":"1999","journal-title":"Anticancer Res."},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(91)90391-P"},{"key":"e_1_2_7_34_2","first-page":"89","article-title":"Colchine in the experimental chemotherapy of cancer","volume":"6","author":"Ludford RJ","year":"1945","journal-title":"J Natl Cancer Inst."},{"key":"e_1_2_7_35_2","first-page":"1829","article-title":"Combretastatin A\u20104, an agent that displays potent and selective toxicity toward tumor vasculature","volume":"57","author":"Dark GG","year":"1997","journal-title":"Cancer Res."},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00320-4"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00299-5"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1999.tb00851.x"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)02742-6"},{"key":"e_1_2_7_40_2","first-page":"1974","article-title":"Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models","volume":"8","author":"Blakey DC","year":"2002","journal-title":"Clin Cancer Res."},{"key":"e_1_2_7_41_2","first-page":"1626","article-title":"Combretastatin A\u20104 phosphate as a tumor vascular\u2010targeting agent: early effects in tumors and normal tissues","volume":"59","author":"Tozer GM","year":"1999","journal-title":"Cancer Res."},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1080\/09553000010007695"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(03)00769-7"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6692174"},{"key":"e_1_2_7_45_2","first-page":"93","article-title":"Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo","volume":"21","author":"Galbraith SM","year":"2001","journal-title":"Anticancer Res."},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)03920-2"},{"key":"e_1_2_7_47_2","first-page":"5537","article-title":"Role of tumor necrosis factor in flavone acetic acid\u2010induced tumor vasculature shutdown","volume":"50","author":"Mahadevan V","year":"1990","journal-title":"Cancer Res."},{"key":"e_1_2_7_48_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF00689199","article-title":"Induction of tumour necrosis factor \u03b1 by single and repeated doses of the antitumor agent 5,6\u2010dimethylxanthenone\u20104\u2010acetic acid","volume":"36","author":"Philpott M","year":"1995","journal-title":"Cancer Chemother Pharmacol."},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/81.13.1005"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/81.3.216"},{"key":"e_1_2_7_51_2","first-page":"870","article-title":"Induction of tumor necrosis factor \u03b1 messenger RNA in human and murine cells by the flavone acetic analogue 5,6\u2010dimethylxanthenone\u20104\u2010acetic acid (NSC64088)","volume":"54","author":"Ching LM","year":"1994","journal-title":"Cancer Res."},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.512"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1667\/0033-7587(2001)156[0503:ITRBCR]2.0.CO;2"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.234"},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10316"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1080\/028418602317314136"},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(00)01470-X"},{"key":"e_1_2_7_58_2","doi-asserted-by":"publisher","DOI":"10.1053\/srao.2003.50005"},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)90292-5"},{"key":"e_1_2_7_60_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050611"},{"key":"e_1_2_7_61_2","first-page":"229","article-title":"Combination chemotherapy with combretastatin A\u20104 phosphate and 5\u2010fluorouracil in an experimental murine colon adenocarcinoma","volume":"20","author":"Grosios K","year":"2000","journal-title":"Anticancer Res."},{"key":"e_1_2_7_62_2","first-page":"157","article-title":"Combretastatin A\u20104 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma","volume":"8","author":"Nelkin BD","year":"2001","journal-title":"Oncol Rep."},{"key":"e_1_2_7_63_2","doi-asserted-by":"publisher","DOI":"10.1080\/028418602317314127"},{"key":"e_1_2_7_64_2","first-page":"4716","article-title":"Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A\u20104 3\u2010O\u2010phosphate","volume":"61","author":"Pedley RB","year":"2001","journal-title":"Cancer Res."},{"key":"e_1_2_7_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00358-7"},{"key":"e_1_2_7_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(01)00384-X"},{"key":"e_1_2_7_67_2","doi-asserted-by":"publisher","DOI":"10.3109\/02656738909140442"},{"key":"e_1_2_7_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)03926-3"},{"key":"e_1_2_7_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01742-4"},{"key":"e_1_2_7_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(00)00318-2"},{"key":"e_1_2_7_71_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.neo.7900123"},{"key":"e_1_2_7_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)03919-6"},{"key":"e_1_2_7_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(02)82471-9"},{"key":"e_1_2_7_74_2","first-page":"3408","article-title":"A Phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A\u20104 phosphate on a single\u2010dose intravenous schedule in patients with advanced cancer","volume":"62","author":"Dowlati A","year":"2002","journal-title":"Cancer Res."},{"key":"e_1_2_7_75_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.185"},{"key":"e_1_2_7_76_2","first-page":"110a","article-title":"Clinical evaluation of the novel vascular\u2010targeting agent ZD6126: assessment of toxicity and surrogate markers of vascular damage [abstract]","volume":"21","author":"Radema SA","year":"2002","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_7_77_2","first-page":"110a","article-title":"A dose\u2010escalation study of the novel vascular\u2010targeting agent ZD6126 in patients with solid tumors [abstract]","volume":"21","author":"Gadgeel SM","year":"2002","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_7_78_2","first-page":"208","article-title":"Phase I, pharmacokinetic, and DCE\u2010MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28 days [abstract]","volume":"22","author":"Tolcher AW","year":"2003","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_7_79_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.187"},{"key":"e_1_2_7_80_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.186"},{"key":"e_1_2_7_81_2","first-page":"111a","article-title":"MRI evaluation of the effects of the vascular\u2010targeting agent ZD6126 on tumor vasculature [abstract]","volume":"21","author":"DelProposto Z","year":"2002","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_7_82_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.144"},{"key":"e_1_2_7_83_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600885"},{"key":"e_1_2_7_84_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600992"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.20299","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.20299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:27:43Z","timestamp":1760300863000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.20299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,2]]},"references-count":83,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2004,6,15]]}},"alternative-id":["10.1002\/cncr.20299"],"URL":"https:\/\/doi.org\/10.1002\/cncr.20299","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6,2]]}}}